Addition of constitutional symptoms to the SLEDAI-2K improves overall disease activity assessment: A pilot study.

Systemic lupus erythematosus outcome measures systemic lupus erythematosus disease activity index

Journal

Lupus
ISSN: 1477-0962
Titre abrégé: Lupus
Pays: England
ID NLM: 9204265

Informations de publication

Date de publication:
25 Apr 2024
Historique:
medline: 26 4 2024
pubmed: 26 4 2024
entrez: 25 4 2024
Statut: aheadofprint

Résumé

Constitutional symptoms (fatigue, lymphadenopathy, and weight loss) are not included in the SLE disease activity index-2000 (SLEDAI-2K). In this pilot study, we assessed the concurrent and construct validity of a revised SLEDAI-2K (SLED-R) that included these symptoms with the original SLEDAI-2K (SLED-O), using the physician global assessment of disease activity (PGA) as the reference. Our revised SLED-R substituted the SLED-O's fever descriptor with a constitutional descriptor that included fever, fatigue, lymphadenopathy, and/or weight loss. SLED-O, SLED-R, PGA and patient global assessment (PtGA) scores were collected prospectively. Bland-Altman correlations for repeated measures were calculated and Meng's z-test was used to compare correlations between dependent and overlapping correlation coefficients. Associations between constitutional symptoms and disease activity measures were analyzed using Mann-Whitney U, Kruskal-Wallis, Chi-square tests and repeated measures correlations. 1123 SLED-O, SLED-R, PGA, and 1066 PtGA were collected in 239 subjects. The new descriptor was scored in 45 subjects (18.8%) and 92 instances (8.1%), while the original descriptor, fever, was scored in only 4 subjects (1.7%) and 5 instances (0.4%). Mean SLED-O, PGA and PtGA scores were higher when the constitutional descriptor was scored versus not ( The addition of constitutional symptoms to SLEDAI-2K, particularly fatigue, resulted in a marginal increase in its correlation with PGA, and new constitutional symptoms associated with higher SLED-O and PGA scores. As fatigue is subjective and difficult to attribute to SLE, its validity and inter-rater reliability in scoring remains uncertain. The clinical utility of SLED-R remains unclear, and further studies of its validity and reliability are needed.

Identifiants

pubmed: 38664230
doi: 10.1177/09612033241249785
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9612033241249785

Déclaration de conflit d'intérêts

Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Erik W Anderson (EW)

Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Manhasset, NY, United States.

Marissa Sansone (M)

Divison of Rheumatology, Jersey City Medical Center, Jersey City, NJ, United States.

Bhakti Shah (B)

Division of Rheumatology, Northwell Health, Manhasset, NY, United States.

Myriam Kline (M)

Biostatistics Unit, Office of Academic Affairs, Northwell Health, New Hyde Park, NY, United States.

Giovanni Franchin (G)

Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Manhasset, NY, United States.

Cynthia Aranow (C)

Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Manhasset, NY, United States.

Meggan Mackay (M)

Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Manhasset, NY, United States.

Classifications MeSH